Unnamed: 0 int64 0 350k | level_0 int64 0 351k | ApplicationNumber int64 9.75M 96.1M | ArtUnit int64 1.6k 3.99k | Abstract stringlengths 1 8.37k | Claims stringlengths 3 292k | abstract-claims stringlengths 68 293k | TechCenter int64 1.6k 3.9k |
|---|---|---|---|---|---|---|---|
700 | 700 | 12,385,856 | 1,631 | A conformation analysis device and analysis method with which discrimination can be achieved even if there is a subtle difference in a conformational structure, a given molecule can be processed in a unified manner, and large-scale computer processing can be performed, and a conformational notation device and notation ... | 1. A conformation analysis method characterized in that:
a processing section receives an input of a chemical structural formula of a compound to be analyzed; the processing section puts a predetermined code indicating a dihedral angle to each chemical binding site based on the received chemical structural formula, ext... | A conformation analysis device and analysis method with which discrimination can be achieved even if there is a subtle difference in a conformational structure, a given molecule can be processed in a unified manner, and large-scale computer processing can be performed, and a conformational notation device and notation ... | 1,600 |
701 | 701 | 14,749,966 | 1,628 | The present invention provides a triazolopyridine compound having a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability. The present invention relates to a compound represented by the following formula [I]:
... | 1. A compound represented by the following formula [I], or a pharmaceutically acceptable salt thereof, or a solvate thereof:
wherein
the partial structural formula:
is a group represented by any of the following formulas:
R1 is
(1) a hydrogen atom,
(2) a C1-6 alkyl group,
(3) a C6-14 ary... | The present invention provides a triazolopyridine compound having a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability. The present invention relates to a compound represented by the following formula [I]:
... | 1,600 |
702 | 702 | 15,102,511 | 1,618 | The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to a method of purifying a radiotracer which comprises 18 F-labelled aminoxy-functionalised biological targeting moiety. The invention provides radioprotectant-containing radiopharmaceutical compositions of the tracer... | 1. A method of purification of a radiotracer which comprises the following steps:
(a) provision of a radiotracer which comprises an 18F-labelled aminoxy-functionalised biological targeting moiety; (b) adding a radioprotectant to said radiotracer to give a radiotracer solution which comprises said radiotracer in one or ... | The present invention relates to the field of radiopharmaceuticals for in vivo imaging, in particular to a method of purifying a radiotracer which comprises 18 F-labelled aminoxy-functionalised biological targeting moiety. The invention provides radioprotectant-containing radiopharmaceutical compositions of the tracer... | 1,600 |
703 | 703 | 15,634,114 | 1,626 | A dibenzo[f,h]quinoxaline derivative in which impurities are reduced and a novel method of synthesizing the dibenzo[f,h]quinoxaline derivative in which impurities are reduced are provided. In addition, a light-emitting element, a light-emitting device, an electronic appliance, or a lighting device with high emission ef... | 1. A light-emitting element comprising:
a pair of electrodes; and an EL layer between the pair of electrodes, wherein the EL layer contains a dibenzo[f,h]quinoxaline derivative, wherein the dibenzo[f,h]quinoxaline derivative includes hydrogen at a 3-position and an aryl group at a 2-position of a dibenzo[f,h]quinoxalin... | A dibenzo[f,h]quinoxaline derivative in which impurities are reduced and a novel method of synthesizing the dibenzo[f,h]quinoxaline derivative in which impurities are reduced are provided. In addition, a light-emitting element, a light-emitting device, an electronic appliance, or a lighting device with high emission ef... | 1,600 |
704 | 704 | 14,978,590 | 1,651 | Provided herein, inter alia, are compositions and kits comprising a bacterial cell and a tumor penetrating agent. Also provided are methods of treating cancer in a subject including the step of administering to the subject an effective amount of a bacterial cell and a tumor penetrating agent. Provided are methods of st... | 1. A method of treating cancer in a subject comprising administering to the subject a combined effective amount of a bacterial cell and a tumor penetrating agent, wherein administration treats the cancer in the subject. 2. The method of claim 1, wherein the combined effective amount is a combined synergistic amount. 3.... | Provided herein, inter alia, are compositions and kits comprising a bacterial cell and a tumor penetrating agent. Also provided are methods of treating cancer in a subject including the step of administering to the subject an effective amount of a bacterial cell and a tumor penetrating agent. Provided are methods of st... | 1,600 |
705 | 705 | 15,559,395 | 1,612 | The present disclosure related to a method of treating bladder cancer in a subject in need of treatment, by administering to the subject an amount of a prodrug of mitomycin C that yields a therapeutically effective amount of mitomycin C. In one embodiment, the prodrug of mitomycin C is a liposomal-prodrug of mitomycin ... | 1. A method for treating bladder cancer, comprising:
administering to an individual with bladder cancer liposomes comprising a folate targeting moiety and a prodrug of mitomycin C, the liposomes administered in an amount that yields a therapeutically-effective amount of mitomycin C for the treatment of bladder cancer. ... | The present disclosure related to a method of treating bladder cancer in a subject in need of treatment, by administering to the subject an amount of a prodrug of mitomycin C that yields a therapeutically effective amount of mitomycin C. In one embodiment, the prodrug of mitomycin C is a liposomal-prodrug of mitomycin ... | 1,600 |
706 | 706 | 14,884,445 | 1,631 | A system and method are for analyzing fluorescence of fluorophors in an eye using a non-negative matrix factorization (NMF) method. The NMF method may be initialized with Gaussian mixture model fits and may optionally be constrained to provide identical abundance images for data obtained in response to two or more exci... | 1. A method for analyzing fluorescence of fluorophors in an eye, comprising:
obtaining, from a plurality of hyperspectral sensors, a first data matrix representative of a first electromagnetic emission spectrum from the fluorophors in response to an excitation signal; isolating a second data matrix from the first data ... | A system and method are for analyzing fluorescence of fluorophors in an eye using a non-negative matrix factorization (NMF) method. The NMF method may be initialized with Gaussian mixture model fits and may optionally be constrained to provide identical abundance images for data obtained in response to two or more exci... | 1,600 |
707 | 707 | 15,235,478 | 1,631 | A bioinformatics process which provides an improved means to detect NFkB cellular signaling pathway in a subject, such as a human, based on the expression levels of at least six unique target genes of the NFkB cellular signaling pathway measured in a sample. The invention includes an apparatus comprising a digital proc... | 1. A computer implemented method for determining the activity level of a NFkB cellular signaling pathway in a subject performed by a computerized device having a processor comprising:
a. calculating an activity level of NFkB transcription factor element in a sample isolated from the subject, wherein the activity level ... | A bioinformatics process which provides an improved means to detect NFkB cellular signaling pathway in a subject, such as a human, based on the expression levels of at least six unique target genes of the NFkB cellular signaling pathway measured in a sample. The invention includes an apparatus comprising a digital proc... | 1,600 |
708 | 708 | 12,175,716 | 1,627 | A process for obtaining an increase in the concentration and/or production of milk protein and/or improving reproductive performance. The process includes administering to a mammal a composition including at least one unsaturated fatty acid, or a derivative thereof, and at least one feed supplement, wherein the combina... | 1. A process for obtaining an increase the concentration and/or production of milk protein characterized by the fact of feeding mammalians with one or more unsaturated fatty acids with 18 carbons molecule or its derivatives with metabolic modifying functions, associated or not with one or more vegetable or animal oils,... | A process for obtaining an increase in the concentration and/or production of milk protein and/or improving reproductive performance. The process includes administering to a mammal a composition including at least one unsaturated fatty acid, or a derivative thereof, and at least one feed supplement, wherein the combina... | 1,600 |
709 | 709 | 12,944,937 | 1,612 | Example embodiments of the present invention include methods, devices, and systems that provide effective dental treatments to all tooth surfaces of the entire dental arch. In particular, embodiments of the present invention include treatment devices and systems that are capable of treating the entire arch by covering ... | 1. A dental treatment system, comprising:
a front portion treatment strip that fully covers one or more teeth on a front portion of a user's dental arch; at least one back portion treatment strip that fully covers one or more teeth on a back portion of the user's dental arch. 2. The dental treatment system recited in c... | Example embodiments of the present invention include methods, devices, and systems that provide effective dental treatments to all tooth surfaces of the entire dental arch. In particular, embodiments of the present invention include treatment devices and systems that are capable of treating the entire arch by covering ... | 1,600 |
710 | 710 | 15,318,897 | 1,617 | The invention relates to a method for coating plant seed, to a seed coating composition, to a coated plant seed, to a use of one or more water-insoluble polymers with a T g of at least 35° C., to a method of preparing a seed coating composition, to a method of preparing coated seed, to coated seed, to a use of an abra... | 1. A method for coating plant seed, comprising applying to said seed a seed coating composition comprising one or more water-insoluble polymers with a Tg of at least 35° C. 2. A method according to claim 1, wherein the seed coating composition has a Minimum Film Forming Temperature (MFFT) at least 10° C. lower than the... | The invention relates to a method for coating plant seed, to a seed coating composition, to a coated plant seed, to a use of one or more water-insoluble polymers with a T g of at least 35° C., to a method of preparing a seed coating composition, to a method of preparing coated seed, to coated seed, to a use of an abra... | 1,600 |
711 | 711 | 12,918,159 | 1,653 | A method for detecting at least one microorganism that may be present in a sample, comprising the steps of:
a) bringing into contact, in a container: a culture medium that enables the growth and/or detection of microorganisms, said sample and a sensitized solid support;
b) subjecting the whole to a temperat... | 1. A method for detecting at least one microorganism that may be present in a sample, comprising the steps of:
a) bringing into contact, in a container: a culture medium that enables the growth and/or detection of microorganisms, said sample and a sensitized solid support; b) subjecting the whole to a temperature that ... | A method for detecting at least one microorganism that may be present in a sample, comprising the steps of:
a) bringing into contact, in a container: a culture medium that enables the growth and/or detection of microorganisms, said sample and a sensitized solid support;
b) subjecting the whole to a temperat... | 1,600 |
712 | 712 | 15,823,918 | 1,613 | A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the conte... | 1. A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant;
wherein the pharmacologically active compound is a stimulant; wherein the pharmacologically active compound is dispersed in a matrix comprisi... | A tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, a polyalkylene oxide, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the conte... | 1,600 |
713 | 713 | 15,331,759 | 1,612 | Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents... | 1. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam, wherein the amide-type local anesthetic and meloxicam are present in the composition at a ratio ranging from about 10:1 to 50:1. 2. The composition of claim 1, wherein the amide-type local anesthetic is bupivaca... | Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents... | 1,600 |
714 | 714 | 16,212,056 | 1,624 | The present invention is directed towards the hemisulfate salt of 5,10-methylene-(6R)-tetrahydrofolic acid, preferably in substantially crystalline form, as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy. | 1-17. (canceled) 18. A method for the prevention of cancer or for controlling cancer comprising administering a hemisulfate salt of 5,10-methylene-(6R)-tetrahydrofolic acid to a subject in need of such treatment. 19. A hemisulfate salt of 5,10-methylene-(6R)-tetrahydrofolic acid, which is in a form readily administrabl... | The present invention is directed towards the hemisulfate salt of 5,10-methylene-(6R)-tetrahydrofolic acid, preferably in substantially crystalline form, as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.1-17. (canceled) 18. A method for the prevention of cancer or for controll... | 1,600 |
715 | 715 | 15,702,697 | 1,612 | Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents... | 1. A composition, consisting essentially of: a delivery vehicle, an amide-type local anesthetic, and a non-steroidal anti-inflammatory drug (NSAID), wherein the ratio of the amide-type local anesthetic to the NSAID ranges from about 15:1 to 50:1, and wherein the NSAID is present in the composition in an amount between ... | Compositions comprised of a delivery vehicle or delivery system and an active agent dispersed within the delivery vehicle or system, wherein the delivery vehicle or system contains a polyorthoester polymer and a polar aprotic solvent. Also disclosed are low viscosity delivery systems for administration of active agents... | 1,600 |
716 | 716 | 15,577,522 | 1,649 | The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and/or 2′,3′-cyclic-nucleotide 3′-phosphodiesterase and/or phosphorylated tau or fragments thereof and methods using thereof for diagnosing, staging, treating and assessing the response of a treatment for a neurocognit... | 1-30. (canceled) 31. A kit comprising reagents for assaying and/or measuring in a sample one or more biomarkers of a panel comprising:
i) a protein phosphatase 1 regulatory subunit 14A comprising the amino acid sequence of SEQ ID NO:1 or an isoform, a variant or a fragment thereof; and/or ii) a 2′,3′-cyclic-nucleotide ... | The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and/or 2′,3′-cyclic-nucleotide 3′-phosphodiesterase and/or phosphorylated tau or fragments thereof and methods using thereof for diagnosing, staging, treating and assessing the response of a treatment for a neurocognit... | 1,600 |
717 | 717 | 14,858,164 | 1,619 | Foaming sunscreen compositions of the present invention include a continuous water phase containing from about 0.75% to about 6% of a superhydrophilic amphiphilic copolymer and a discontinuous oil phase dispersed in the water phase, which oil phase contains a UV-absorbing compound, and which foaming sunscreen compositi... | 1. A foaming sunscreen composition, comprising:
an oil-in-water emulsion, comprising
a continuous water phase comprising from about 0.75% to about 6% by weight of a superhydrophilic amphiphilic copolymer, based on total weight of the foaming sunscreen composition; and
a discontinuous oil phase dispersed in the water ph... | Foaming sunscreen compositions of the present invention include a continuous water phase containing from about 0.75% to about 6% of a superhydrophilic amphiphilic copolymer and a discontinuous oil phase dispersed in the water phase, which oil phase contains a UV-absorbing compound, and which foaming sunscreen compositi... | 1,600 |
718 | 718 | 15,314,414 | 1,618 | The concentration of an administered compound, such as a drug (D), in an organ or a bodily fluid, such as blood, is determined directly through detecting the drug (D) or its metabolites (DM) in sweat. The concentration may be determined indirectly by administering the drug (D) together with one or more tracer compounds... | 1. A method of determining a concentration of a primary drug administered to a patient comprising:
administering to said patient a known amount of said primary drug; administering to said patient a known amount of at least one tracer compound; detecting a concentration of said at least one tracer compound or a metaboli... | The concentration of an administered compound, such as a drug (D), in an organ or a bodily fluid, such as blood, is determined directly through detecting the drug (D) or its metabolites (DM) in sweat. The concentration may be determined indirectly by administering the drug (D) together with one or more tracer compounds... | 1,600 |
719 | 719 | 14,245,276 | 1,613 | A hair care composition comprising from about 0.25% to about 80% of a pre-emulsified emulsion comprising from about 0.005% to about 80% of one or more materials selected from the group comprising metathesized unsaturated polyol esters, sucrose polyesters, fatty esters with a molecular weight greater than or equal to 15... | 1) A hair care composition comprising:
a. from about 0.25% to about 80% of a pre-emulsified emulsion comprising from about 0.005% to about 80% of one or more materials selected from the group comprising metathesized unsaturated polyol esters, sucrose polyesters, fatty esters with a molecular weight greater than or equa... | A hair care composition comprising from about 0.25% to about 80% of a pre-emulsified emulsion comprising from about 0.005% to about 80% of one or more materials selected from the group comprising metathesized unsaturated polyol esters, sucrose polyesters, fatty esters with a molecular weight greater than or equal to 15... | 1,600 |
720 | 720 | 15,793,340 | 1,624 | This invention relates to a process for the production of a high purity polyether carbonate polyol. The high purity polyether carbonate polyols prepared by the process herein contain a low level of catalyst residue. The process purifies polyether carbonate polyol through use of activated carbon, mixed into the polyethe... | 1. A process for producing a high purity polyether carbonate polyol which contains a low level of catalyst residue, comprising
(1) adding from 0.1% to 10% by weight, based on 100% by weight of polyether carbonate polyol, of activated carbon, to the polyether carbonate polyol; (2) mixing the composition formed in (1) fo... | This invention relates to a process for the production of a high purity polyether carbonate polyol. The high purity polyether carbonate polyols prepared by the process herein contain a low level of catalyst residue. The process purifies polyether carbonate polyol through use of activated carbon, mixed into the polyethe... | 1,600 |
721 | 721 | 13,803,716 | 1,627 | A drink product having as an active ingredient an inositol hexaphosphate and optionally additional inositol moieties. Hexaphosphates for use in the invention include myoinositol hexaphosphate and/or any of the other 8 optical isomers thereof. The optional additional inositols include myoinositol and/or any of the other... | 1. An aqueous liquid formulation comprising:
(a) water and (b) myoinositol hexaphosphate and/or an optical isomer thereof, and/or an orally acceptable salt thereof, further optionally comprising one or more components selected from the group consisting of:
(1) myoinositol and/or an optical isomer;
(2) an orally accepta... | A drink product having as an active ingredient an inositol hexaphosphate and optionally additional inositol moieties. Hexaphosphates for use in the invention include myoinositol hexaphosphate and/or any of the other 8 optical isomers thereof. The optional additional inositols include myoinositol and/or any of the other... | 1,600 |
722 | 722 | 14,431,534 | 1,627 | Provided is a method of treating and/or preventing Wolfram Syndrome (WS)-related neurodegeneration (i.e. of Wolfram Syndrome-Associated Neuronal Degeneration), by increasing the expression and/or functional activity of p21. A method of screening for pharmacological agents useful in treating and/or preventing such condi... | 1. A compound capable of increasing the expression and/or functional activity of p21 for use in the treatment and/or prevention of Wolfram Syndrome (WS)-related neurodegeneration. 2. A compound for use according to claim 1, where the compound is capable of increasing the expression; increasing the binding; increasing t... | Provided is a method of treating and/or preventing Wolfram Syndrome (WS)-related neurodegeneration (i.e. of Wolfram Syndrome-Associated Neuronal Degeneration), by increasing the expression and/or functional activity of p21. A method of screening for pharmacological agents useful in treating and/or preventing such condi... | 1,600 |
723 | 723 | 12,798,027 | 1,647 | The invention relates to medicine. The inventive agent which exhibits immunoregulatory properties and accelerated clinical performance at a recrudescence stage and is mainly used for treating autoimmune diseases comprises trophoblastic β-1-glycoprotein and immunoglobulin (Ig) which is embodied in the form of a multival... | 1. An agent with the property to induce the suppressor activity and cytokine secretion of mononuclear cells that contains trophoblastic β-1-glycoprotein (TBG), distinctive in that it also contains immunoglobulin (Ig). 2. An agent per item 1, distinctive in that immunoglobulin class G (Ig-G), or class A (Ig-A), or class... | The invention relates to medicine. The inventive agent which exhibits immunoregulatory properties and accelerated clinical performance at a recrudescence stage and is mainly used for treating autoimmune diseases comprises trophoblastic β-1-glycoprotein and immunoglobulin (Ig) which is embodied in the form of a multival... | 1,600 |
724 | 724 | 14,701,248 | 1,631 | Systems, methods, and apparatuses are provided for determining a sequence of a heteropolymer molecule. For example, all or part of a chromosome or a protein can be determined using sequence data from a plurality of heteropolymer fragments corresponding to the heteropolymer molecule. As one example, a position in the se... | 1. A method comprising performing, by a computer system:
receiving sequence data from a sequencing of a plurality of heteropolymer fragments corresponding to a heteropolymer molecule of an organism, wherein the sequence data for each heteropolymer fragment of the plurality of heteropolymer fragments includes:
intensity... | Systems, methods, and apparatuses are provided for determining a sequence of a heteropolymer molecule. For example, all or part of a chromosome or a protein can be determined using sequence data from a plurality of heteropolymer fragments corresponding to the heteropolymer molecule. As one example, a position in the se... | 1,600 |
725 | 725 | 13,972,274 | 1,627 | A drink product having as an active ingredient genistein and an inositol hexaphosphate and/or an unphosphorylated inositol and optionally additional inositol (unphosphorylated as well as hexaphosphorylated) moieties. Hexaphosphates for use in the invention include myoinositol hexaphosphate and/or any of the other 8 opt... | 1. An aqueous liquid formulation comprising:
(a) water and (b) myoinositol hexaphosphate and/or an optical isomer thereof, and/or an orally acceptable salt thereof, (c) Genistein (d) further optionally comprising one or more components selected from the group consisting of:
(1) myoinositol and/or an optical isomer;
(2)... | A drink product having as an active ingredient genistein and an inositol hexaphosphate and/or an unphosphorylated inositol and optionally additional inositol (unphosphorylated as well as hexaphosphorylated) moieties. Hexaphosphates for use in the invention include myoinositol hexaphosphate and/or any of the other 8 opt... | 1,600 |
726 | 726 | 15,498,728 | 1,646 | A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequenc... | 1. A method of treatment or prophylaxis of cancer in a patient comprising administering to the patient at least one selected from the group consisting of:
a) a polypeptide comprising a sequence selected from the group consisting of:
i) SEQ, ID NOS. 2, 3, 4, 7 or 8;
ii) the sequence of an immunogenic fragment of i) comp... | A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequenc... | 1,600 |
727 | 727 | 16,120,120 | 1,612 | Compositions for upregulating defensin expression include oleic acid and linoleic acid. The compositions can be in a liposomal, nanoliposomal, or nanoemulsion form. The compositions are useful in preventing, treating and ameliorating defensin-related conditions, such as preventing and treating HIV infection. | 1. A pharmaceutical composition for upregulating defensin expression, comprising oleic acid and linoleic acid, the composition being in a form of a nanoliposome, wherein the nanoliposome has an average particle size of 150 nm. 2. (canceled) 3. The pharmaceutical composition according to claim 1, wherein the nanoliposom... | Compositions for upregulating defensin expression include oleic acid and linoleic acid. The compositions can be in a liposomal, nanoliposomal, or nanoemulsion form. The compositions are useful in preventing, treating and ameliorating defensin-related conditions, such as preventing and treating HIV infection.1. A pharma... | 1,600 |
728 | 728 | 15,241,260 | 1,661 | A watermelon plant that produces fruit having (i) ultra-firm flesh and/or liquid-retaining flesh and (ii) soluble solids of at least about 6 brix. | 1. A watermelon plant, or a part thereof, that produces a mature fruit having flesh that resists pressure of at least 3.5 pounds force (lbf) and has soluble solids of at least 6 brix. 2. (canceled) 3. The watermelon plant, or part thereof, of claim 1 wherein said flesh resists pressure of at least 4.0 lbf. 4. The water... | A watermelon plant that produces fruit having (i) ultra-firm flesh and/or liquid-retaining flesh and (ii) soluble solids of at least about 6 brix.1. A watermelon plant, or a part thereof, that produces a mature fruit having flesh that resists pressure of at least 3.5 pounds force (lbf) and has soluble solids of at leas... | 1,600 |
729 | 729 | 15,558,700 | 1,653 | What is disclosed is a method of reducing undesirable concentrations of microorganisms without the use of man-made antibiotics, comprising the steps of: introducing a quantity of fermentable carbohydrate; sugar or cellulose to an aqueous system; introducing a quantity of desirable microorganism to the aqueous system; i... | 1. A method of controlling undesirable microorganism concentration in an aqueous fluid solution employed in a fermentation process, the method comprising the steps of:
introducing a fermentable carbohydrate to the aqueous fluid solution; introducing at least one desirable microorganism that is capable of fermenting car... | What is disclosed is a method of reducing undesirable concentrations of microorganisms without the use of man-made antibiotics, comprising the steps of: introducing a quantity of fermentable carbohydrate; sugar or cellulose to an aqueous system; introducing a quantity of desirable microorganism to the aqueous system; i... | 1,600 |
730 | 730 | 15,518,080 | 1,699 | The present invention relates to a catalytic process for the ethynylation of specific poly-unsaturated aldehydes and ketones. | 1. A catalytic ethynylation of a compound of formula (I)
wherein
R1 signifies —H, —CH3 or —CH2CH3, and
R2 signifies —H, —CH3 or —CH2CH3, and
R3 signifies a moiety
with ethyne
in the presence of a catalyst of formula ROH, wherein
R signifies K or Cs, and
wherein NH3 is used as solvent. 2. Catalytic ... | The present invention relates to a catalytic process for the ethynylation of specific poly-unsaturated aldehydes and ketones.1. A catalytic ethynylation of a compound of formula (I)
wherein
R1 signifies —H, —CH3 or —CH2CH3, and
R2 signifies —H, —CH3 or —CH2CH3, and
R3 signifies a moiety
with ethyne... | 1,600 |
731 | 731 | 15,509,438 | 1,629 | The invention provides therapeutic methods comprising the administration of thymol or carvacrol, or a pharmaceutically acceptable salt or prodrug thereof. The methods are useful for modulating muscle atrophy, performance, recovery, generation, or maintenance in animals. | 1. A method comprising modulating muscle atrophy, performance, recovery, generation, or maintenance in an animal in need thereof by administering thymol or carvacrol, or a pharmaceutically acceptable salt or prodrug thereof to the animal. 2. The method of claim 1 wherein the animal is a human. 3. The method of claim 1 ... | The invention provides therapeutic methods comprising the administration of thymol or carvacrol, or a pharmaceutically acceptable salt or prodrug thereof. The methods are useful for modulating muscle atrophy, performance, recovery, generation, or maintenance in animals.1. A method comprising modulating muscle atrophy, ... | 1,600 |
732 | 732 | 14,773,497 | 1,644 | The disclosure relates generally to methods and compositions of treating or preventing diabetes mellitus by administering to a subject a composition comprising an amount of stem and/or progenitor cells and at least one antigen-specific therapy. | 1. A method of treating or preventing diabetes mellitus in a subject, the method comprising: administering to the subject a composition comprising an amount of one or more stem and/or progenitor cells and an amount of at least one antigen-specific therapy. 2. The method of claim 1, wherein the diabetes mellitus is type... | The disclosure relates generally to methods and compositions of treating or preventing diabetes mellitus by administering to a subject a composition comprising an amount of stem and/or progenitor cells and at least one antigen-specific therapy.1. A method of treating or preventing diabetes mellitus in a subject, the me... | 1,600 |
733 | 733 | 15,111,328 | 1,642 | The present invention primarily relates to a method for stratification of a patient for assessing the suitability of a therapy. The invention also relates to a method for the prognosis of the outcome of a disease of a patient and a method for the prediction and/or detection of therapy resistance of a patient towards a ... | 1. A method for stratification of a patient for assessing the suitability of a therapy for the patient suffering from an ER and/or PR positive and HER2 negative cancer, the therapy being directed towards a signaling pathway, comprising the following step:
(i) determining the activation status of an ER and/or PR signali... | The present invention primarily relates to a method for stratification of a patient for assessing the suitability of a therapy. The invention also relates to a method for the prognosis of the outcome of a disease of a patient and a method for the prediction and/or detection of therapy resistance of a patient towards a ... | 1,600 |
734 | 734 | 15,677,809 | 1,626 | Disclosed are benzimidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure
and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (an... | 1. A compound having the structure of formula (I):
or a pharmaceutically acceptable salt, prodrug or N-oxide thereof, or solvate or hydrate thereof, wherein
R1 and R2 together with the atoms to which they are attached form ring A, wherein ring A is a 5- or 6-membered Het optionally substituted with one or mo... | Disclosed are benzimidazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure
and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (an... | 1,600 |
735 | 735 | 13,129,544 | 1,639 | A process for removing by-products from N-vinylamide-rich product mixtures (crude N-vinylamide), which comprises performing an extraction of the crude N-vinylamide with an organic solvent as the extractant. | 1. A process for removing by-products from a N-vinylamide-rich product mixture, which comprises extracting the crude N-vinylamide with an organic solvent as the extractant. 2. The process according to claim 1, wherein the N-vinylamide comprises cyclic N-vinylamides (vinyllactams) or noncyclic N-vinylamides of the formu... | A process for removing by-products from N-vinylamide-rich product mixtures (crude N-vinylamide), which comprises performing an extraction of the crude N-vinylamide with an organic solvent as the extractant.1. A process for removing by-products from a N-vinylamide-rich product mixture, which comprises extracting the cru... | 1,600 |
736 | 736 | 14,209,056 | 1,616 | The invention relates to a method for the production of carrier pellets for pharmaceutical active substances. Likewise, the invention relates to such carrier pellets and also to pharmaceutical formulations containing these. The carrier pellets according to the invention are used for transporting and releasing pharmaceu... | 1. A method for the production of carrier pellets for a pharmaceutically active substance, the method comprising:
a) producing a liquid formulation by dissolving, dispersing, or a combination of dissolving and dispersing at least one physiologically well-tolerated pH regulator in at least one solvent or emulsifier; b) ... | The invention relates to a method for the production of carrier pellets for pharmaceutical active substances. Likewise, the invention relates to such carrier pellets and also to pharmaceutical formulations containing these. The carrier pellets according to the invention are used for transporting and releasing pharmaceu... | 1,600 |
737 | 737 | 15,800,407 | 1,645 | Administration of an antibody that specifically binds IL-1α is useful for reducing the chance or severity of a major adverse clinical event occurring in a mammalian subject having received or expected to receive surgical treatment for a stenosed blood vessel, and for reducing the change of restenosis occurring (or incr... | 1. A method of reducing the chance of a major adverse clinical event occurring in a human subject having received or expected to receive surgical treatment for a stenosed blood vessel, the method comprising the step of repeatedly administering to the subject a 0.2 to 20 mg/kg dose of a pharmaceutical composition compri... | Administration of an antibody that specifically binds IL-1α is useful for reducing the chance or severity of a major adverse clinical event occurring in a mammalian subject having received or expected to receive surgical treatment for a stenosed blood vessel, and for reducing the change of restenosis occurring (or incr... | 1,600 |
738 | 738 | 16,205,602 | 1,628 | Provided herein is a method for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a therapeutically effective amount of a drug chosen from a P-gp substrate, BCRP substrate, OAT2 substrate, OAT4 substrate, OCT1 subs... | 1. A method for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to treat a disease chosen from primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants in a subject in need thereof, wherein the subject is also being administered a therapeutical... | Provided herein is a method for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered a therapeutically effective amount of a drug chosen from a P-gp substrate, BCRP substrate, OAT2 substrate, OAT4 substrate, OCT1 subs... | 1,600 |
739 | 739 | 15,024,567 | 1,616 | An agrochemical formulation comprising an agricultural active and an adjuvant is disclosed. The adjuvant comprises a residue of sorbitan or sorbitan derivative having at least one active hydrogen atom replaced to form an ethyloxylated or propoxylated ester. The adjuvant and methods of treating crops with an agrochemica... | 1.-5. (canceled) 6. An agrochemical formulation comprising;
i) an adjuvant; and ii) at least one agrochemical active;
wherein said adjuvant has general structure (I):
Sorb.(AO1H)n1(AO2H)n3(AO3H)n3(AO4R1)n4 (I)
wherein:
Sorb represents a residue of a sorbitan or sorbitan derivative;
AO1, AO2, AO3, and AO4 each inde... | An agrochemical formulation comprising an agricultural active and an adjuvant is disclosed. The adjuvant comprises a residue of sorbitan or sorbitan derivative having at least one active hydrogen atom replaced to form an ethyloxylated or propoxylated ester. The adjuvant and methods of treating crops with an agrochemica... | 1,600 |
740 | 740 | 15,035,633 | 1,613 | A composition comprising:
(a) a hydrogen peroxide source (b) an acetyl source (c) a peracetic acid bleachable dye
wherein, in solution, colour generated by said peracetic acid bleachable dye is substantially discharged when a biocidally effective concentration of peracetic acid is achieved. | 1. A composition comprising:
(a) a hydrogen peroxide source (b) an acetyl source (c) a peracetic acid bleachable dye wherein, in solution, colour generated by said peracetic acid bleachable dye is substantially discharged when a biocidally effective concentration of peracetic acid is achieved. 2. A composition accordin... | A composition comprising:
(a) a hydrogen peroxide source (b) an acetyl source (c) a peracetic acid bleachable dye
wherein, in solution, colour generated by said peracetic acid bleachable dye is substantially discharged when a biocidally effective concentration of peracetic acid is achieved.1. A compositi... | 1,600 |
741 | 741 | 13,980,593 | 1,612 | This disclosure relates to compounds and compositions for forming bone and methods related thereto. In certain embodiments, the disclosure relates to methods of forming bone comprising implanting a bone graft composition comprising a growth factor such as BMP in a subject at a site of desired bone growth or enhancement... | 1. A bone graft composition comprising a quinoline derivative, 4-(phenoxy)-quinoline derivative, N-phenylquinolin-4-amine derivative, N2-(phenyl)-N4-(phenyl)pyrimidine-2,4-diamine derivative, 3-(benzylidene)indolin-2-one derivative, 2-((phenylamino)methylene)malononitrile derivative, 2-benzylidenemalononitrile derivati... | This disclosure relates to compounds and compositions for forming bone and methods related thereto. In certain embodiments, the disclosure relates to methods of forming bone comprising implanting a bone graft composition comprising a growth factor such as BMP in a subject at a site of desired bone growth or enhancement... | 1,600 |
742 | 742 | 16,200,233 | 1,648 | The invention relates to an influenza vaccine composition for spray-administration to nasal mucosa, which comprises an inactivated whole influenza virion and a gel base material comprising carboxy vinyl polymer, which is characterized by not comprising an adjuvant. | 1-10. (canceled) 11. A method for preventing influenza in a human subject, comprising:
administering to the human subject an influenza vaccine composition comprising: (i) an inactivated whole influenza virion; and (ii) a gel base material comprising carboxy vinyl polymer
that is prepared by treating the gel base mater... | The invention relates to an influenza vaccine composition for spray-administration to nasal mucosa, which comprises an inactivated whole influenza virion and a gel base material comprising carboxy vinyl polymer, which is characterized by not comprising an adjuvant.1-10. (canceled) 11. A method for preventing influenza ... | 1,600 |
743 | 743 | 15,521,787 | 1,617 | The invention relates to an oil-based cleansing product which contains abrasive particles as exfoliating substances. In one particular embodiment, salt and sugar crystals are used as exfoliating substances. | 1.-20. (canceled) 21. A skin cleansing preparation, wherein the preparation has an abrasive effect, comprises less than 5% of water and comprises
(a) one or more lipids, (b) one or more polyols, (c) one or more oil-soluble surfactants, (d) one or more kinds of abrasive particles, and (e) one or more polymeric structura... | The invention relates to an oil-based cleansing product which contains abrasive particles as exfoliating substances. In one particular embodiment, salt and sugar crystals are used as exfoliating substances.1.-20. (canceled) 21. A skin cleansing preparation, wherein the preparation has an abrasive effect, comprises less... | 1,600 |
744 | 744 | 14,420,518 | 1,618 | Provided is an antimicrobial non-isotactic polymer based hard or semi-flexible surface in a thermoset and/or thermoplastic resin matrix wherein the active antimicrobial ingredient is copper oxide! Processes for preparing the same and applications thereof are also described. The invention is directed to polymeric solid ... | 1. A composite structural solid material comprising a polymeric resin and copper oxide particles substantially uniformly dispersed therein optionally further comprising a filler material, wherein said copper oxide is present at a concentration ranging from 10 to 50% w/w % and wherein a portion of said copper oxide part... | Provided is an antimicrobial non-isotactic polymer based hard or semi-flexible surface in a thermoset and/or thermoplastic resin matrix wherein the active antimicrobial ingredient is copper oxide! Processes for preparing the same and applications thereof are also described. The invention is directed to polymeric solid ... | 1,600 |
745 | 745 | 11,464,704 | 1,613 | A process for manufacturing and using pancreatin micropellet cores and pancreatin micropellets which are substantially free of synthetic oils. In one embodiment, a pharmaceutical composition is provided comprising a pancreatin micropellet with the enteric coating being designed to deliver pancreatin to the upper portio... | 1. A process for the manufacture of pancreatin micropellet cores, comprising the steps of:
a. preparing an extrudable mixture comprising:
i. about 10% to about 95% pancreatin;
ii. about 5% to about 90% of at least one pharmaceutically acceptable binding agent;
iii. 0% to about 10% of at least one pharmaceutically a... | A process for manufacturing and using pancreatin micropellet cores and pancreatin micropellets which are substantially free of synthetic oils. In one embodiment, a pharmaceutical composition is provided comprising a pancreatin micropellet with the enteric coating being designed to deliver pancreatin to the upper portio... | 1,600 |
746 | 746 | 10,940,892 | 1,631 | Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design... | 1. A kit for gene silencing, wherein said kit is comprised of a pool of at least two siRNA duplexes, each of which is comprised of a sequence that is complementary to a portion of the sequence of one or more target messenger RNA, and each of which is selected using selection criteria that are embodied in a formula comp... | Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design... | 1,600 |
747 | 747 | 13,867,308 | 1,611 | Tablets are prepared with friability reducing agents to yield tablets that are more resistant to breakage or crumbling, but with satisfactory hardness. The friability reducing agents include low molecular weight polyethylene glycol as well as similar agents exhibiting at least three percent (3%) hydroxide moieties and ... | 1. A tablet exhibiting reduced friability, comprising an active agent, an excipient compatible with said active agent, and an agent to reduce friability, wherein said agent to reduce friability is present in amounts of about 0.1%-about 5.0% by weight of the tablet, said friability reducing agent comprises a compound wh... | Tablets are prepared with friability reducing agents to yield tablets that are more resistant to breakage or crumbling, but with satisfactory hardness. The friability reducing agents include low molecular weight polyethylene glycol as well as similar agents exhibiting at least three percent (3%) hydroxide moieties and ... | 1,600 |
748 | 748 | 15,315,777 | 1,653 | The invention concerns plant wax extracts and a method for extracting wax from plants, such as agricultural biowaste and in particular from cereal straw, including a first dry mechanical treatment step to separate a wax enriched fraction from a straw fraction low in wax and a second wet step including enzymatic treatme... | 1. A method for separating wax-containing plant material into a wax fraction and a fiber fraction partly depleted of wax, comprising:
a. mechanically treating plant material in a dry process at ambient temperature to provide comminuted plant material, b. separating the comminuted plant material into a fraction A compri... | The invention concerns plant wax extracts and a method for extracting wax from plants, such as agricultural biowaste and in particular from cereal straw, including a first dry mechanical treatment step to separate a wax enriched fraction from a straw fraction low in wax and a second wet step including enzymatic treatme... | 1,600 |
749 | 749 | 15,593,586 | 1,612 | Provided herein are methods for preparing liposomes comprising increased concentration of hydrophobic therapeutic agents and improved stability, and uses thereof. In certain embodiments, liposomes are prepared without using heat, organic solvents, proteins, and/or inorganic salts. | 1. A method of incorporating a hydrophobic therapeutic agent into preformed liposomes, the method comprising the steps of:
(a) providing (i) a liposome suspension comprising a plurality of preformed liposomes suspended in an aqueous medium, the liposomes comprising lipid forming a lipid bilayer phase, and (ii) a solid ... | Provided herein are methods for preparing liposomes comprising increased concentration of hydrophobic therapeutic agents and improved stability, and uses thereof. In certain embodiments, liposomes are prepared without using heat, organic solvents, proteins, and/or inorganic salts.1. A method of incorporating a hydropho... | 1,600 |
750 | 750 | 15,308,445 | 1,646 | Excessive or repeated activation of inflammatory and pro-coagulant mechanisms at the site of tissue injury contributes to the development scar tissue that can lead to intimal hyperplasia and fibrotic disease. It has been established that inhibition of the LYST protein is associated with reduced inflammatory responses a... | 1. A pharmaceutical composition comprising:
a) one or more inhibitors of LYST in an amount effective to reduce or prevent macrophage infiltration, natural killer cells and to reduce or prevent platelet activation in a subject in a subject; and b) a physiologically acceptable carrier, wherein the amount of one or more i... | Excessive or repeated activation of inflammatory and pro-coagulant mechanisms at the site of tissue injury contributes to the development scar tissue that can lead to intimal hyperplasia and fibrotic disease. It has been established that inhibition of the LYST protein is associated with reduced inflammatory responses a... | 1,600 |
751 | 751 | 15,683,210 | 1,612 | The present invention pertains to a pharmaceutical composition comprising the compound of the formula (I) in a high concentration and at least one pharmaceutically acceptable excipient, the use of the composition for the treatment of hyper-proliforative diseases, such as cancer, either as a sole agent, or in combinatio... | 1. A pharmaceutical composition comprising 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide, its solvates, hydrates, pharmaceutically acceptable salts, or a combination thereof as active agent in a portion of at least 40% by weight of the composition and at least one ph... | The present invention pertains to a pharmaceutical composition comprising the compound of the formula (I) in a high concentration and at least one pharmaceutically acceptable excipient, the use of the composition for the treatment of hyper-proliforative diseases, such as cancer, either as a sole agent, or in combinatio... | 1,600 |
752 | 752 | 15,724,502 | 1,615 | A benzimidazole formulation which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach, and which has low levels of residual volatile excipients, including but not limited to residual alkalinizing agents and/or residual solvents. | 1. A stable composition for a benzimidazole derivative, the composition comprising:
a substrate, said substrate comprising the benzimidazole derivative, and a single coating layer consisting essentially of one or more enteric polymers selected from the group consisting of cellulose acetate phthalate (CAP), hydroxypropy... | A benzimidazole formulation which lacks an intermediate layer and yet which is stable both during storage and during the passage through the stomach, and which has low levels of residual volatile excipients, including but not limited to residual alkalinizing agents and/or residual solvents.1. A stable composition for a... | 1,600 |
753 | 753 | 15,418,412 | 1,663 | The invention relates to methods of producing a desired phenotype in a plant by manipulation of gene expression within the plant. The method relates to means which increase the level of expression of a MYB-subgroup14 polynucleotide or a MYB68 polypeptide. The method also relates to expression of a nucleic acid sequence... | 1. A method of producing a heat stress tolerant plant, comprising:
a) providing a nucleic acid encoding a MYB subgroup-14 polypeptide selected from the group consisting of MYB36, MYB37, MYB38, MYB68, MYB84, and MYB87; b) inserting said nucleic acid into a vector; c) transforming a plant, a tissue culture, or a plant ce... | The invention relates to methods of producing a desired phenotype in a plant by manipulation of gene expression within the plant. The method relates to means which increase the level of expression of a MYB-subgroup14 polynucleotide or a MYB68 polypeptide. The method also relates to expression of a nucleic acid sequence... | 1,600 |
754 | 754 | 15,188,239 | 1,653 | Methods are provided for detecting enzymatic activity of various lysosomal storage enzymes using substrates that include: a sugar moiety; a linker moiety allowing the conjugation of sugar moiety with the remaining structure of the substrate; and two or more fatty acid chains or derivatives thereof at least one of which... | 1. A method for detecting enzymatic activity, comprising:
contacting a sample containing a target enzyme with a substrate, under conditions wherein the target enzyme is capable of acting on the substrate to produce an enzymatic product; and detecting said enzymatic product; the substrate having formula:
wher... | Methods are provided for detecting enzymatic activity of various lysosomal storage enzymes using substrates that include: a sugar moiety; a linker moiety allowing the conjugation of sugar moiety with the remaining structure of the substrate; and two or more fatty acid chains or derivatives thereof at least one of which... | 1,600 |
755 | 755 | 15,664,146 | 1,626 | An additive composition comprises phosphate ester anions conforming to a specified structure, aromatic carboxylate anions, optionally cycloaliphatic dicarboxylate anions, aluminum (III) cations, sodium cations, optionally calcium cations, optionally lithium cations, and optionally zinc (II) cations. The anions are pres... | 1. An additive composition comprising:
(a) phosphate ester anions conforming to the structure of Formula (I)
wherein R1 and R2 are independently selected from the group consisting of hydrogen and C1-C18 alkyl groups, and R3 is an alkanediyl group;
(b) aromatic carboxylate anions;
(c) aluminum (III) cations;... | An additive composition comprises phosphate ester anions conforming to a specified structure, aromatic carboxylate anions, optionally cycloaliphatic dicarboxylate anions, aluminum (III) cations, sodium cations, optionally calcium cations, optionally lithium cations, and optionally zinc (II) cations. The anions are pres... | 1,600 |
756 | 756 | 14,400,846 | 1,618 | Monolayer protected nanoclusters (MPCs) are described herein. The MPCs contain a cluster of atoms or molecules (e.g. core) having bound thereto a plurality of ligands (e.g., monolayer). The ligands can be bound covalently or semi-covalently bound to the cluster. The ligands are generally in the form of a monolayer or m... | 1. Water-soluble monolayer protected nanoclusters comprising clusters and a plurality of water-soluble ligands bound to the clusters, wherein the quantum efficiency of the near-IR luminescence is greater than 1%, preferably greater than 3%, single clusters can be imaged, or combinations thereof. 2. Organo-soluble monol... | Monolayer protected nanoclusters (MPCs) are described herein. The MPCs contain a cluster of atoms or molecules (e.g. core) having bound thereto a plurality of ligands (e.g., monolayer). The ligands can be bound covalently or semi-covalently bound to the cluster. The ligands are generally in the form of a monolayer or m... | 1,600 |
757 | 757 | 15,179,696 | 1,613 | Methods and compositions are provided that are utilized for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury. In particular, the methods and compositions are inhibitors of a particular NC Ca-ATP channel and include, for exam... | 1.-48. (canceled) 49. A method of targeting a plasma level of glyburide in an individual, comprising the step of administering glyburide to the individual as follows:
(a) an intravenous loading dose of glyburide; and (b) a maintenance dose of glyburide, which is different than the loading dose. 50. The method of claim ... | Methods and compositions are provided that are utilized for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury. In particular, the methods and compositions are inhibitors of a particular NC Ca-ATP channel and include, for exam... | 1,600 |
758 | 758 | 14,373,413 | 1,618 | The present invention relates to a method of labelling biological molecules with 18 F, via attachment to fluorine to a macrocyclic metal complex of a non-radioactive metal, where the metal complex is conjugated to the biological molecule. Also provided are pharmaceutical compositions, kits and methods of in vivo imagi... | 1. An imaging agent which comprises an 18F-labelled compound of Formula I:
where:
Y1 and Y2 are independently O or NR1,
X1, X2 and X3 are independently Br, Cl, 19F or 18F,
with the proviso that at least one of X1, X2 and X3 is 18F;
x, y and z are independently 0, 1 or 2;
M is Al3+, Ga3+, In3+, Sc3+, Y3+, Ho... | The present invention relates to a method of labelling biological molecules with 18 F, via attachment to fluorine to a macrocyclic metal complex of a non-radioactive metal, where the metal complex is conjugated to the biological molecule. Also provided are pharmaceutical compositions, kits and methods of in vivo imagi... | 1,600 |
759 | 759 | 14,377,723 | 1,612 | The present invention relates to an effective formulation for the treatment or the prevention of irritable bowel syndrome, a method for treating irritable bowel syndrome, and processes for preparing such formulations. | 1. A composition for treatment and/or prevention of irritable bowel syndrome comprising resins and/or extracts thereof, polysaccharides and/or plant extracts comprising polysaccharides, antioxidants and/or plant extracts comprising antioxidants. 2. The composition according to claim 1 wherein said resins or extracts th... | The present invention relates to an effective formulation for the treatment or the prevention of irritable bowel syndrome, a method for treating irritable bowel syndrome, and processes for preparing such formulations.1. A composition for treatment and/or prevention of irritable bowel syndrome comprising resins and/or e... | 1,600 |
760 | 760 | 15,429,671 | 1,642 | The present invention relates to therapeutic ADCs comprising a drug attached to an anti-cancer antibody or antigen-binding antibody fragment. Preferably the drug is SN-38. More preferably the antibody or fragment thereof binds to Trop-2 and the therapy is used to treat a Trop-2 positive cancer. Most preferably the anti... | 1. A method of treating a Trop-2 positive cancer comprising:
a. administering to a human patient with a Trop-2 positive cancer an anti-Trop-2 antibody-drug conjugate (ADC) comprising an anti-cancer drug conjugated to an anti-Trop-2 antibody or antigen-binding fragment thereof; and b. administering to the patient an ABC... | The present invention relates to therapeutic ADCs comprising a drug attached to an anti-cancer antibody or antigen-binding antibody fragment. Preferably the drug is SN-38. More preferably the antibody or fragment thereof binds to Trop-2 and the therapy is used to treat a Trop-2 positive cancer. Most preferably the anti... | 1,600 |
761 | 761 | 14,353,299 | 1,653 | The present invention relates to an anaerobic process for biogas upgrading and hydrogen utilization comprising the use of acidic waste as co-substrate. In this process, H 2 and CO 2 will be converted to CH 4 , which will result in lower CO 2 content in the biogas. The invention relates to both in situ and ex situ me... | 1. A method of manufacturing an upgraded biogas, said method comprising the steps of:
a. initiating an anaerobic digestion process in a bioreactor comprising:
i. substrate,
ii. anaerobic inoculum comprising anaerobic hydrogenotrophic methanogenic organisms,
b. feeding the bioreactor with an acidic waste substrate to m... | The present invention relates to an anaerobic process for biogas upgrading and hydrogen utilization comprising the use of acidic waste as co-substrate. In this process, H 2 and CO 2 will be converted to CH 4 , which will result in lower CO 2 content in the biogas. The invention relates to both in situ and ex situ me... | 1,600 |
762 | 762 | 13,059,753 | 1,631 | A method of characterizing a population of antibodies to an antigen comprises contacting a sensor surface having the antigen immobilized thereto with a sample containing the antibody population to bind antibodies to the surface, and detecting dissociation of antibodies from the sensor surface during a dissociation phas... | 1. A method of characterizing a population of antibodies to an antigen, which comprises providing a sensor surface having the antigen immobilized thereto, contacting the sensor surface with a sample containing the antibody population to bind antibodies to the surface, detecting dissociation of antibodies from the senso... | A method of characterizing a population of antibodies to an antigen comprises contacting a sensor surface having the antigen immobilized thereto with a sample containing the antibody population to bind antibodies to the surface, and detecting dissociation of antibodies from the sensor surface during a dissociation phas... | 1,600 |
763 | 763 | 14,917,643 | 1,648 | A method for measuring influenza B virus by an immunoassay, which method enables specific detection of influenza B virus with a higher sensitivity than conventional methods, and a device or a kit therefor are disclosed. The method for measuring influenza B virus includes carrying out an immunoassay of influenza B virus... | 1. A method for measuring influenza B virus, said method comprising carrying out an immunoassay of influenza B virus by a sandwich method using two kinds of monoclonal antibodies each of which specifically reacts with the region of the 125th to 248th amino acids of matrix protein (M1) of influenza B virus, said two kin... | A method for measuring influenza B virus by an immunoassay, which method enables specific detection of influenza B virus with a higher sensitivity than conventional methods, and a device or a kit therefor are disclosed. The method for measuring influenza B virus includes carrying out an immunoassay of influenza B virus... | 1,600 |
764 | 764 | 14,855,355 | 1,618 | Compositions, formulations and kits comprising chlorotoxin conjugate compounds are provided, including native and modified variants of chlorotoxin peptide conjugated to reporter molecules including fluorescent dyes. Methods of detecting and treating cancers and tumors with chlorotoxin conjugate compounds are also provi... | 1. A compound having the structure of Formula (III), or a pharmaceutically acceptable salt thereof:
wherein:
R1, R2, R3, R4, R5, R6, R7, R8, R15, and R16 are each independently selected from hydrogen, C1-C6 alkyl, C1-C6 alkylene-COOH, sulfonate, —COOH, —SO2—NH2, or C1-C6 alkoxy;
R9 is hydrogen, sulfonate, or... | Compositions, formulations and kits comprising chlorotoxin conjugate compounds are provided, including native and modified variants of chlorotoxin peptide conjugated to reporter molecules including fluorescent dyes. Methods of detecting and treating cancers and tumors with chlorotoxin conjugate compounds are also provi... | 1,600 |
765 | 765 | 14,271,021 | 1,658 | A hair care composition having from about from about 0.025% to about 0.25% by weight of the composition of histidine. The hair care composition further includes a gel matrix phase. The gel matrix has from about 0.1% to about 20% of one or more high melting point fatty compounds, from about 0.1% to about 10% of a C22 ca... | 1. A hair care composition comprising:
a. from about 0.025% to about 0.25% by weight of the composition of histidine; b. a gel matrix comprising:
i. from about 0.1% to about 20% of one or more high melting point fatty compounds, by weight of said hair care composition;
ii. from about 0.1% to about 10% a cationic surfac... | A hair care composition having from about from about 0.025% to about 0.25% by weight of the composition of histidine. The hair care composition further includes a gel matrix phase. The gel matrix has from about 0.1% to about 20% of one or more high melting point fatty compounds, from about 0.1% to about 10% of a C22 ca... | 1,600 |
766 | 766 | 15,567,496 | 1,642 | An object of the present invention is to identify a cancer antigen protein specifically expressed on the surface of cancer cells and provide use of an antibody targeting the cancer antigen protein as a therapeutic and/or prophylactic agent for cancer. A pharmaceutical composition for treating and/or preventing cancer c... | 1. A pharmaceutical composition for treating and/or preventing cancer, comprising an antibody or a fragment thereof having immunological reactivity with CSPG5 protein or a fragment thereof consisting of at least 7 or more consecutive amino acid residues, as an active ingredient. 2. The pharmaceutical composition accord... | An object of the present invention is to identify a cancer antigen protein specifically expressed on the surface of cancer cells and provide use of an antibody targeting the cancer antigen protein as a therapeutic and/or prophylactic agent for cancer. A pharmaceutical composition for treating and/or preventing cancer c... | 1,600 |
767 | 767 | 14,171,766 | 1,639 | System, including methods and apparatus, for spacing droplets from each other and for detection of spaced droplets. | 1. A particle singulator, comprising
a particle channel including a particle inlet configured to receive particles suspended in a carrier fluid; a shell surrounding at least a portion of the particle channel; and a plurality of dilution channels formed within the shell and configured to transport dilution fluid to the ... | System, including methods and apparatus, for spacing droplets from each other and for detection of spaced droplets.1. A particle singulator, comprising
a particle channel including a particle inlet configured to receive particles suspended in a carrier fluid; a shell surrounding at least a portion of the particle chann... | 1,600 |
768 | 768 | 15,478,041 | 1,636 | A method of determining a beating parameter of cells that undergo excitation contraction coupling, the method including providing a cell analysis device having a substrate and a sensor that measures cell adhesion or attachment to the substrate in millisecond time resolution; adding excitable cells capable of undergoing... | 1. A method of determining a beating parameter of cells that undergo excitation contraction coupling, the method comprising:
a) providing a cell analysis device comprising a substrate and a sensor that measures cell adhesion or attachment to the substrate in millisecond time resolution; b) adding excitable cells capabl... | A method of determining a beating parameter of cells that undergo excitation contraction coupling, the method including providing a cell analysis device having a substrate and a sensor that measures cell adhesion or attachment to the substrate in millisecond time resolution; adding excitable cells capable of undergoing... | 1,600 |
769 | 769 | 14,333,608 | 1,618 | The present invention relates to a pigment mixture based on spherical particles having a defined particle-size distribution, and to the use thereof in paints, coatings, printing inks, security printing inks, plastics, ceramic materials, glasses, in cosmetic formulations, as tracer, as filler and for the preparation of ... | 1. A pigment mixture comprising at least two components A and B:
component A is spherical base particles having a particle-size distribution D90 of uncoated particles of 0.5-15 μm, said particles being coated on their surface firstly with TiO2 and subsequently with SiO2, and component B is spherical base particles havi... | The present invention relates to a pigment mixture based on spherical particles having a defined particle-size distribution, and to the use thereof in paints, coatings, printing inks, security printing inks, plastics, ceramic materials, glasses, in cosmetic formulations, as tracer, as filler and for the preparation of ... | 1,600 |
770 | 770 | 14,494,170 | 1,628 | The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound valaciclovir and a therapeutically-effective amount of the COX-2 inhibitor celecoxib. The invention is further related to methods of treating functional somatic syndromes... | 1-21. (canceled) 22. A method to treat a subject susceptible to or afflicted with fibromyalgia, the method comprising administering to the subject a therapeutically-effective co-acting combination of valaciclovir and celecoxib, wherein each of valaciclovir and celecoxib is administered in an amount in combination effec... | The present invention relates to pharmaceutical compositions comprising a combination of a therapeutically-effective amount of the antiviral compound valaciclovir and a therapeutically-effective amount of the COX-2 inhibitor celecoxib. The invention is further related to methods of treating functional somatic syndromes... | 1,600 |
771 | 771 | 14,138,026 | 1,658 | The monofunctional branched poly(ethylene glycol) (PEG) has a general formula shown in formula (1), and the bio-related substance modified by the monofunctional branched PEG has a general fomula shown in formula (2), wherein X 1 and X 2 are each independently a hydrocarbon group having 1 to 20 carbon atoms, n 1 and ... | 1. A monofunctional branched poly(ethylene glycol) (PEG) represented by general formula (1):
wherein X1 and X2 are each independently an hydrocarbon group having 1 to 20 carbon atoms at a terminal end of the two branch chains, wherein n1 and n2 are each independently an integer selected from 1 to 1000, where... | The monofunctional branched poly(ethylene glycol) (PEG) has a general formula shown in formula (1), and the bio-related substance modified by the monofunctional branched PEG has a general fomula shown in formula (2), wherein X 1 and X 2 are each independently a hydrocarbon group having 1 to 20 carbon atoms, n 1 and ... | 1,600 |
772 | 772 | 14,409,664 | 1,631 | Systems and methods are provided herein for generating a classifier for phenotypic prediction. A computational causal network model representing a biological system includes a plurality of nodes and a plurality of edges connecting pairs of nodes. A first set of data corresponding to activities of a first subset of biol... | 1. A computerized method for identifying biological entities that are representative of a phenotype of interest, comprising the steps of:
(a) providing, at a processing device, a computational causal network model that represents a biological system that contributes to the phenotype and includes: a plurality of nodes t... | Systems and methods are provided herein for generating a classifier for phenotypic prediction. A computational causal network model representing a biological system includes a plurality of nodes and a plurality of edges connecting pairs of nodes. A first set of data corresponding to activities of a first subset of biol... | 1,600 |
773 | 773 | 16,012,988 | 1,617 | Compositions of the present invention include sunscreen compositions containing a primary UV-absorbing agent in an amount effective to absorb ultraviolet (UV) and about 5% or less of a visible light radiation agent that includes a continuous silica-containing coating. | 1-10. (canceled) 11. A method of protecting skin against visible light radiation, which comprises topically applying to skin a sunscreen composition, comprising:
about 1.0% or more of disodium phenyldibenzimidazole tetrasulfonate; and about 0.5 to 2% of a visible light absorbing agent comprising titanium dioxide, where... | Compositions of the present invention include sunscreen compositions containing a primary UV-absorbing agent in an amount effective to absorb ultraviolet (UV) and about 5% or less of a visible light radiation agent that includes a continuous silica-containing coating.1-10. (canceled) 11. A method of protecting skin aga... | 1,600 |
774 | 774 | 15,481,884 | 1,628 | Disclosed herein are cationic steroidal antimicrobials (“CSA compounds” or “ceragenins”) and methods of making the same. Particularly advantageous methods are identified for the synthesis of CSA compounds. CSA compounds may be formulated for treating subjects with ailments responsive to CSA compounds, including but not... | 1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof:
wherein
R1 is selected from the group consisting of an optionally substituted C11-22-alkylamino-Cx-alkyl; an optionally substituted C8-22-alkylester-Cx-alkyl; and optionally substituted Z1, Z2-amino-Cx-alkyl;
R2, R3, and R4, are ind... | Disclosed herein are cationic steroidal antimicrobials (“CSA compounds” or “ceragenins”) and methods of making the same. Particularly advantageous methods are identified for the synthesis of CSA compounds. CSA compounds may be formulated for treating subjects with ailments responsive to CSA compounds, including but not... | 1,600 |
775 | 775 | 14,506,209 | 1,619 | In an embodiment, the present invention is directed a method of achieving hair volume and combability comprising applying to hair a personal care composition comprising from about 0.25% to about 80% of a pre-emulsified emulsion comprising from about 0.005% to about 80% of one or more materials selected from the group c... | 1. A method of achieving hair volume and combability comprising applying to hair a personal care composition comprising:
a) from about 0.25% to about 80% of a pre-emulsified emulsion comprising from about 0.005% to about 80% of one or more materials selected from the group comprising metathesized unsaturated polyol est... | In an embodiment, the present invention is directed a method of achieving hair volume and combability comprising applying to hair a personal care composition comprising from about 0.25% to about 80% of a pre-emulsified emulsion comprising from about 0.005% to about 80% of one or more materials selected from the group c... | 1,600 |
776 | 776 | 13,832,394 | 1,619 | Phenylephrine particles suitable for solid, semi solid or liquid dosage forms are disclosed. | 1. A drug-resin complex comprising phenylephrine and a cation polystyrene sulfonate, wherein said cation polystyrene sulfonate comprises particle sizes of about 74 μm to about 177 μm prior to being combined with the phenylephrine. 2. The drug-resin complex of claim 1, wherein the cation is selected from the group consi... | Phenylephrine particles suitable for solid, semi solid or liquid dosage forms are disclosed.1. A drug-resin complex comprising phenylephrine and a cation polystyrene sulfonate, wherein said cation polystyrene sulfonate comprises particle sizes of about 74 μm to about 177 μm prior to being combined with the phenylephrin... | 1,600 |
777 | 777 | 15,099,737 | 1,617 | An aqueous skin cosmetic product exerting a high irregularity correction effect, providing a non-greasy and light feeling when applied and having an excellent sebum suppressing effect is provided. The skin cosmetic product of the present invention is characterized by comprising (A) 15 to 50% by mass of a powder formed ... | 1. A skin cosmetic product comprising:
(A) 15 to 50% by mass of a powder formed of an (adipic acid/neopentyl glycol) crosspolymer, and (B) 0.5 to 3% by mass of a hydrophobically modified polyurethane. 2. The skin cosmetic product according to claim 1, wherein:
the hydrophobically modified polyurethane is (PEG-240/Decyl... | An aqueous skin cosmetic product exerting a high irregularity correction effect, providing a non-greasy and light feeling when applied and having an excellent sebum suppressing effect is provided. The skin cosmetic product of the present invention is characterized by comprising (A) 15 to 50% by mass of a powder formed ... | 1,600 |
778 | 778 | 14,657,523 | 1,623 | A method for digestion of a crude terephthalic slurry obtained from oxidation of para-xylene in a bubble column reactor oxidation process is provided. The method is conducted in one or more bubble column reactors having one or more segregrated zones defined by horizontal baffles and particle flow through the digestion ... | 1. A method for purification of crude terephthalic acid comprising:
a) obtaining a digester feed slurry of particles of crude terephthalic acid, comprising terephthalic acid, 4-carboxybenzaldehyde and p-toluic acid in a solvent liquid comprising aqueous acetic acid and a catalyst system comprising at least one heavy me... | A method for digestion of a crude terephthalic slurry obtained from oxidation of para-xylene in a bubble column reactor oxidation process is provided. The method is conducted in one or more bubble column reactors having one or more segregrated zones defined by horizontal baffles and particle flow through the digestion ... | 1,600 |
779 | 779 | 15,823,272 | 1,644 | An anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes with a Tie2 receptor and Ang2, and related methods and compositions. | 1.-24. (canceled) 25. A method of activating Tie-2 receptor in a subject, comprising administering an anti-Ang2 antibody or an antigen-binding fragment thereof to the subject to form a complex comprising the anti-Ang2 antibody or the antigen-binding fragment thereof, Ang2, and a Tie2 receptor, while inducing Tie2 phosp... | An anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes with a Tie2 receptor and Ang2, and related methods and compositions.1.-24. (canceled) 25. A method of activating Tie-2 receptor in a subject, comprising administeri... | 1,600 |
780 | 780 | 13,419,045 | 1,656 | The present invention relates to improved decorin compositions and methods of their production. | 1. A fusion protein comprising a heterologous signal peptide operably linked to a sequence encoding decorin. 2. The fusion protein of claim 1, wherein said signal sequence is an alpha-lactalbumin signal sequence. 3. The fusion protein of claim 2, wherein said alpha lactalbumin sequence is a bovine alpha-lactalbumin sig... | The present invention relates to improved decorin compositions and methods of their production.1. A fusion protein comprising a heterologous signal peptide operably linked to a sequence encoding decorin. 2. The fusion protein of claim 1, wherein said signal sequence is an alpha-lactalbumin signal sequence. 3. The fusio... | 1,600 |
781 | 781 | 11,315,969 | 1,632 | Cells derived from postpartum tissue and methods for their isolation and induction to differentiate to cells of a chondrogenic or osteogenic phenotype are provided by the invention. The invention further provides cultures and compositions of the postpartum-derived cells and products such as lysates related thereto. The... | 1. A postpartum-derived cell comprising a cell derived from human postpartum tissue substantially free of blood, wherein said cell is capable of self-renewal and expansion in culture and has the potential to differentiate into a cell of an osteogenic or chondrogenic phenotype; wherein said cell requires L-valine for gr... | Cells derived from postpartum tissue and methods for their isolation and induction to differentiate to cells of a chondrogenic or osteogenic phenotype are provided by the invention. The invention further provides cultures and compositions of the postpartum-derived cells and products such as lysates related thereto. The... | 1,600 |
782 | 782 | 14,742,864 | 1,627 | The present invention is directed to an improved effectiveness pharmaceutical carrier comprising anyone or a combination of edible or pharmaceutical acceptable fatty acids and anyone or a combination of non-ionic surfactants, which is capable of improving the bio-absorption of drugs with intermediate log P ranging from... | 1. A pharmaceutical composition comprising:
an edible and pharmaceutically acceptable fatty acid; and a non-ionic surfactant,
wherein the pharmaceutical composition is a self-emulsifying drug delivery system. 2. The pharmaceutical composition of claim 1, further comprising:
a drug, wherein the drug has an intermediate ... | The present invention is directed to an improved effectiveness pharmaceutical carrier comprising anyone or a combination of edible or pharmaceutical acceptable fatty acids and anyone or a combination of non-ionic surfactants, which is capable of improving the bio-absorption of drugs with intermediate log P ranging from... | 1,600 |
783 | 783 | 14,236,828 | 1,615 | The invention relates to a product, method of use, and/or method of preparing a capsule or capsular like product that comprises hydrophilic fluid-absorbing materials that bind, entrap, and/or absorb large quantities of fluid. The capsules or capsular like product may be capable of diverting the mode of fluid and waste ... | 1-64. (canceled) 65. An orally consumable medical product comprising a substantially nitrogen-free capsule containing a water-insoluble fluid-absorbing material. 66. The product of claim 1, wherein the capsules are made from non-animal and/or non-protein based material, wherein the materials contain no protein. 67. The... | The invention relates to a product, method of use, and/or method of preparing a capsule or capsular like product that comprises hydrophilic fluid-absorbing materials that bind, entrap, and/or absorb large quantities of fluid. The capsules or capsular like product may be capable of diverting the mode of fluid and waste ... | 1,600 |
784 | 784 | 14,892,866 | 1,662 | Crop growth management system comprising a process of providing a plant with improved abiotic stress tolerance, comprising providing aerial parts of said plant with a suspension containing cells of an Agrobacterium strain comprising a nucleic acid molecule comprising a nucleic acid construct containing a nucleotide s... | 1. A process of providing a plant with improved abiotic stress tolerance, comprising providing aerial parts of said plant with a suspension containing cells of an Agrobacterium strain comprising a nucleic acid molecule comprising a nucleic acid construct containing a nucleotide sequence of interest, said nucleotide seq... | Crop growth management system comprising a process of providing a plant with improved abiotic stress tolerance, comprising providing aerial parts of said plant with a suspension containing cells of an Agrobacterium strain comprising a nucleic acid molecule comprising a nucleic acid construct containing a nucleotide s... | 1,600 |
785 | 785 | 14,905,394 | 1,663 | Provided are plants that express, or overexpress, type III Gγ protein AGG3. Such plants exhibit faster vegetative and reproductive growth, accompanied by an increase in photosynthetic efficiency. Constitutive or seed-specific expression of AGG3 in Camelina increases seed size, seed mass, and seed number per plant by ... | 1. A transgenic plant, other than a rice plant or Arabidopsis, with enhanced resistance to a redox stress comprising expressing in said transgenic plant a DNA construct comprising a promoter that functions in plants, operably linked to a DNA polynucleotide molecule selected from the group consisting of:
a. a DNA molecu... | Provided are plants that express, or overexpress, type III Gγ protein AGG3. Such plants exhibit faster vegetative and reproductive growth, accompanied by an increase in photosynthetic efficiency. Constitutive or seed-specific expression of AGG3 in Camelina increases seed size, seed mass, and seed number per plant by ... | 1,600 |
786 | 786 | 13,714,243 | 1,637 | A Method for nucleic acid analysis involving the steps of receiving sample tubes which contain samples, receiving a test request for each sample (the test request specifying one or more assays to be conducted for said sample), obtaining one or more sample aliquots of each sample depending on if one or more assays are t... | 1. A method for nucleic add analysis involving the steps of
receiving sample tubes each containing a sample, receiving a test request for each sample, said test request specifying one or more assays to be conducted for said sample, obtaining one or more sample aliquots of each sample depending on if one or more assays ... | A Method for nucleic acid analysis involving the steps of receiving sample tubes which contain samples, receiving a test request for each sample (the test request specifying one or more assays to be conducted for said sample), obtaining one or more sample aliquots of each sample depending on if one or more assays are t... | 1,600 |
787 | 787 | 14,197,339 | 1,619 | Novel mixtures of sugar amides or sugar amines are disclosed that have improved thermal properties over the individual components. New feedstocks based on both the surfactant tail as well as the sugar head group allow for improved physical properties of sugar amide surfactant mixtures and thus improved formulatability.... | 1. A mixture comprising a first chemical and a second chemical, wherein said first chemical has the chemical structure of Formula I and said second chemical has the chemical structure of Formula II:
wherein:
n1 is 2 to 4;
n2 is 1 to 3;
n1 is greater than n2
R1 and R3 are independently selected from hydroge... | Novel mixtures of sugar amides or sugar amines are disclosed that have improved thermal properties over the individual components. New feedstocks based on both the surfactant tail as well as the sugar head group allow for improved physical properties of sugar amide surfactant mixtures and thus improved formulatability.... | 1,600 |
788 | 788 | 15,518,256 | 1,615 | It is an object to provide a therapeutic material for a skin ulcer which has excellent therapeutic effects on intractable skin ulcers such as decubitus ulcers with pockets and huge decubitus ulcers. By applying the therapeutic material for decubitus ulcers consisting of a fibrous material holding an antibiotic and a ce... | 1. A method for treating a skin ulcer, comprising applying a therapeutic material for a skin ulcer consisting of a fibrous material holding an antibiotic and a cell proliferation accelerator therein which is formed into an approximately spherical shape to a site of a skin ulcer in a state in which a defect extending to... | It is an object to provide a therapeutic material for a skin ulcer which has excellent therapeutic effects on intractable skin ulcers such as decubitus ulcers with pockets and huge decubitus ulcers. By applying the therapeutic material for decubitus ulcers consisting of a fibrous material holding an antibiotic and a ce... | 1,600 |
789 | 789 | 14,891,763 | 1,629 | The invention relates to the use of additives in the preparation of crop protection composition spray mixtures, in particular as additives for tank mixtures of specific pesticides according to formula (I), pesticide mixtures and crop protection compositions comprising these pesticides. | 1. A pesticidal composition comprising a tetramic acid compound of the formula (I)
wherein
X, Y and Z independently of each other are C1-4alkyl, C3-6cycloalkyl, C1-4haloalkyl, C1-4alkoxy, halogen, phenyl or phenyl substituted by C1-4alkyl, C1-4haloalkyl, halogen or cyano;
m and n, independently of each other,... | The invention relates to the use of additives in the preparation of crop protection composition spray mixtures, in particular as additives for tank mixtures of specific pesticides according to formula (I), pesticide mixtures and crop protection compositions comprising these pesticides.1. A pesticidal composition compri... | 1,600 |
790 | 790 | 15,098,727 | 1,617 | A silicone composition, especially advantageous for incorporation in a personal care product, includes a silicone resin (a) and a silicone gum (b), the mixture of resin (a) and gum (b) having a softening point of 50° C. or greater and an elastic modulus at ambient temperature of 10 6 Pa or less. | 1-20. (canceled) 21. A composition which comprises:
a) a MT resin having a molecular weight higher than 10,000 and containing one or more M units of the formula R1 3SiO1/2, and T units of the formula R3SiO3/2 wherein the ratio of M to T units ranges from 1:1 to 1:7, and the softening point of the MT resin ranges from 5... | A silicone composition, especially advantageous for incorporation in a personal care product, includes a silicone resin (a) and a silicone gum (b), the mixture of resin (a) and gum (b) having a softening point of 50° C. or greater and an elastic modulus at ambient temperature of 10 6 Pa or less.1-20. (canceled) 21. A ... | 1,600 |
791 | 791 | 15,315,173 | 1,656 | Liquid cleaning agents and methods for cleaning are provided herein. In one embodiment, the liquid cleaning agent includes at least one liquid enzyme formulation which includes at least one protease and/or at least one amylase. The liquid cleaning agent further includes at least one solid enzyme formulation which inclu... | 1. A liquid cleaning agent, comprising:
at least one liquid enzyme formulation which comprises at least one protease and/or at least one amylase; and at least one solid enzyme formulation which comprises at least one protease and/or at least one amylase, wherein the solid enzyme formulation is homogeneously suspended i... | Liquid cleaning agents and methods for cleaning are provided herein. In one embodiment, the liquid cleaning agent includes at least one liquid enzyme formulation which includes at least one protease and/or at least one amylase. The liquid cleaning agent further includes at least one solid enzyme formulation which inclu... | 1,600 |
792 | 792 | 13,546,757 | 1,651 | A flow cytometer system for sorting haploid cells, specifically sperm cells, may include an intermittingly punctuated radiation emitter, such as a pulsed laser. Embodiments include a beam manipulator and even split radiation beams directed to multiple nozzles. Differentiation of sperm characteristics with increased res... | 1-231. (canceled) 232. A method of sorting sperm cells comprising the steps of:
producing a stream of stained sperm cells and sheath fluid; exciting the stained sperm cells within the stream with a pulsed laser; detecting an emitted fluorescence from each of the stained sperm cells; distinguishing between X chromosome ... | A flow cytometer system for sorting haploid cells, specifically sperm cells, may include an intermittingly punctuated radiation emitter, such as a pulsed laser. Embodiments include a beam manipulator and even split radiation beams directed to multiple nozzles. Differentiation of sperm characteristics with increased res... | 1,600 |
793 | 793 | 12,727,824 | 1,634 | The invention generally relates to methods for detecting fetal nucleic acids and methods for diagnosing fetal abnormalities. In certain embodiments, the invention provides methods for determining whether fetal nucleic acid is present in a maternal sample including obtaining a maternal sample suspected to include fetal ... | 1. A method for determining a fetal abnormality, the method comprising:
obtaining a maternal sample; sequencing at least a portion of nucleic acids in the sample; comparing obtained sequence information to a reference sequence; identifying fetal nucleic acid, if present, in the sample; optionally, if fetal nucleic acid... | The invention generally relates to methods for detecting fetal nucleic acids and methods for diagnosing fetal abnormalities. In certain embodiments, the invention provides methods for determining whether fetal nucleic acid is present in a maternal sample including obtaining a maternal sample suspected to include fetal ... | 1,600 |
794 | 794 | 15,150,373 | 1,633 | The present invention provides an expression vector for preventing or inhibiting HIV entry, fusion or replication in mammalian cells. In particular, the invention provides a recombinant retroviral vector that encodes an inhibitor of a HIV co-receptor, such as CCR5 or CXCR4, and a protein that inhibits HIV fusion to tar... | 1. (canceled) 2. A method of treating or preventing HIV infection in a patient comprising (i) transducing hematopoietic cells with an expression vector, the expression vector comprising a first nucleic acid sequence encoding an inhibitor of an HIV co-receptor and a second nucleic acid sequence encoding a protein that i... | The present invention provides an expression vector for preventing or inhibiting HIV entry, fusion or replication in mammalian cells. In particular, the invention provides a recombinant retroviral vector that encodes an inhibitor of a HIV co-receptor, such as CCR5 or CXCR4, and a protein that inhibits HIV fusion to tar... | 1,600 |
795 | 795 | 14,906,089 | 1,627 | The invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: (I). The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various dis... | 1. A compound of formula I
or a pharmaceutically acceptable salt thereof,
wherein, independently for each occurrence:
R1 is H, Cl, CH3, CF3 or cyclopropyl;
R2 is H, F, Cl, CN, CH3, CF3 or CHF2;
R3 is H, F, Cl, CN, CF3, OCF3 or CF2CF3;
R4 is H;
R5 is H, F, Cl, CH3, OCH3, OCH2CH3, OCH2CH2CH3 or OCHF2;
R5′ is H... | The invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: (I). The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various dis... | 1,600 |
796 | 796 | 14,986,904 | 1,619 | In some aspects, the present disclosure pertains to tissue bulking compositions that comprise: (a) solid particles comprising a pH-sensitive polymer that has a pH-dependent solubility such that the solid particles dissolve upon an increase or decrease in pH, (b) a crosslinking agent for the pH-sensitive polymer and (c)... | 1. A tissue bulking composition comprising: (a) solid particles comprising a pH-sensitive polymer that has a pH-dependent solubility such that the solid particles dissolve upon an increase or decrease in pH, (b) a crosslinking agent for the pH-sensitive polymer and (c) a pH modifying agent that generates acid or base i... | In some aspects, the present disclosure pertains to tissue bulking compositions that comprise: (a) solid particles comprising a pH-sensitive polymer that has a pH-dependent solubility such that the solid particles dissolve upon an increase or decrease in pH, (b) a crosslinking agent for the pH-sensitive polymer and (c)... | 1,600 |
797 | 797 | 10,876,998 | 1,632 | Cells derived from postpartum tissue and methods for their isolation and induction to differentiate to cells of a chondrogenic or osteogenic phenotype are provided by the invention. The invention further provides cultures and compositions of the postpartum-derived cells and products related thereto. The postpartum-deri... | 1. A postpartum-derived cell comprising a cell derived from human postpartum tissue substantially free of blood, wherein said cell is capable of self-renewal and expansion in culture and has the potential to differentiate into a cell of an osteogenic or chondrogenic phenotype; wherein said cell requires L-valine for gr... | Cells derived from postpartum tissue and methods for their isolation and induction to differentiate to cells of a chondrogenic or osteogenic phenotype are provided by the invention. The invention further provides cultures and compositions of the postpartum-derived cells and products related thereto. The postpartum-deri... | 1,600 |
798 | 798 | 14,312,749 | 1,619 | The present invention provides an oral care composition, containing at least 0.5% by weight of silica agglomerates, wherein each of the silica agglomerates has: (i) an overall particle size from 200 μm to 2000 μm, and (ii) a crush strength from 0.1N to 5N. The silica particles that make up the silica agglomerate can ha... | 1. An oral care composition, comprising at least 0.5% by weight of silica agglomerates, wherein each of the silica agglomerates has: (i) an overall particle size from 200 μm to 2000 μm, and (ii) a crush strength from 0.1N to 5N; wherein silica particles that make up the silica agglomerates have an average particle size... | The present invention provides an oral care composition, containing at least 0.5% by weight of silica agglomerates, wherein each of the silica agglomerates has: (i) an overall particle size from 200 μm to 2000 μm, and (ii) a crush strength from 0.1N to 5N. The silica particles that make up the silica agglomerate can ha... | 1,600 |
799 | 799 | 13,855,846 | 1,619 | Hard shell capsules filled with a pharmaceutical medicament and at least one modifier, selected to prevent abuse of the medicament are described. The modifier may have a high melting point, and therefore melt at a temperature too high to inject or be insoluble in liquid, having a density less than 1, to prevent “spikin... | 1.-26. (canceled) 27. An abuse resistant capsule comprising a hard shell capsule filled with a composition comprising at least one pharmaceutical medicament, at least one waxy substance having melting point greater than about 50° C., present in an amount ranging from about 10% to about 98.8% w/w, and at least one water... | Hard shell capsules filled with a pharmaceutical medicament and at least one modifier, selected to prevent abuse of the medicament are described. The modifier may have a high melting point, and therefore melt at a temperature too high to inject or be insoluble in liquid, having a density less than 1, to prevent “spikin... | 1,600 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.